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is able to oppose the vasodilator effect of bradykinin. ThisGlomerular autacoids stimulated by bradykinin regulate effer-
vasodilator effect is mediated by EETs released by the glomer-ent arteriole tone.
ulus and/or the efferent arteriole and does not involve nitricBackground. We have shown that when efferent arterioles
oxide. The balance between these opposing effects of variousare perfused retrograde to avoid the influence of vasoactive
eicosanoids controls efferent arteriole resistance downstreamautacoids released by the glomerulus, bradykinin causes dilata-
tion via release of cytochrome P450 (cP450) metabolites, prob- from the glomerulus.
ably epoxyeicosatrienoic acids (EETs). Here we tested the
hypothesis that the glomerulus releases cyclooxygenase (COX)
and cP450 metabolites. These eicosanoids, acting as vasopres- We have shown that bradykinin dilates the efferent
sor and vasodepressor autacoids, control efferent arteriole re- arteriole when it is perfused retrograde, which eliminates
sistance downstream from the glomerulus. the influence of vasoactive autacoids released by theMethods. Rabbit efferent arterioles were perfused orthograde
glomerulus [20]. The vasodilator effect of bradykininthrough the glomerulus from the end of the afferent arteriole
is mediated by the release of epoxyeicosatrienoic acidsto determine whether bradykinin induces the release of glomer-
ular autacoids that influence efferent arteriole resistance. Effer- (EETs) from the efferent arteriole and does not involve
ent arterioles were preconstricted with norepinephrine, and either nitric oxide (NO) or cyclooxygenase (COX) me-
increasing doses of bradykinin were added to the perfusate in tabolites. However, we have also shown that the glomer-the presence or absence of COX and cP450 inhibitors.
ulus releases vasoactive substances that regulate the re-Results. When efferent arterioles were perfused orthograde
sistance of the downstream efferent arteriole and maythrough the glomerulus, bradykinin at 10 nmol/L caused sig-
nificant and reproducible dilatation; diameter increased from thereby help control its capillary pressure [2, 10]. Recent
8.0  0.5 to 12.6  0.4 m (P  0.05). This effect was not studies have indicated that glomerular COX [11] and
modified by a nitric oxide synthase (NOS) inhibitor. In the lipoxygenase [1] produce arachidonic acid metabolitespresence of indomethacin, a COX inhibitor, bradykinin-induced
[24]. Both mRNA and protein for cytochrome P450dilatation was almost completely blocked (from 8.0  0.5 to
(cP450) enzymes are also expressed in the glomeruli [9],9.3  0.6 m). This blockade was completely reversed by
20-hydroxyeicosa-6(Z),15(Z)-dienoic acid (20-HEDE), a spe- indicating that they can produce vasoactive substances
cific antagonist of the vasoconstrictor cP450 metabolite 20- via this pathway as well. Furthermore, NO produced by
hydroxyeicosatetraenoic acid (20-HETE); diameter increased endothelial cells lining the glomerular capillaries mayfrom 6.6  0.7 to 13.2  0.5 m. To test the hypothesis that
reach the efferent arteriole in sufficient quantities tothis dilatation was due to EETs, a specific inhibitor of EET
induce dilatation. The release of vasoactive autacoids bysynthesis, N-methylsulphonyl-6-(2-proparglyloxyphenyl)hex-
anamide (MS-PPOH), was added to the arteriolar perfusate. the glomerulus may be stimulated by bradykinin, angio-
In the presence of indomethacin and 20-HEDE, bradykinin tensin, and/or shear stress. Renal kinins are released at
caused dilatation and this effect was completely blocked by both the luminal and basolateral sides of the nephronMS-PPOH (1 m) (from 7.6  0.6 to 7.3  0.5 m).
by kallikrein, which is located mainly in the connectingConclusions. We concluded that in response to bradykinin,
tubule [16, 23]. The connecting tubule is situated closethe glomerulus releases COX metabolites (probably prosta-
glandins) that have a vasodilator effect. When COXs are inhib- to the glomerular tuft, and studies have shown that kalli-
ited, the vasoconstrictor 20-HETE released by the glomerulus krein from the connecting tubule enters the vascular
space as well as the interstitium [12, 19]. Thus, kinins
Key words: glomerulus, efferent arteriole, cP450, COX. released in this area of the nephron could stimulate the
release of vasoactive autacoids from the glomerulus; theseReceived for publication January 25, 2002
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efferent arteriole resistance by releasing COX and cP450
metabolites of arachidonic acid when stimulated with
bradykinin, rabbit efferent arterioles were perfused or-
thograde through the glomerulus from the end of the
afferent arteriole. The vasodilator effect of bradykinin
on efferent arteriole diameter was studied while inhib-
iting nitric oxide synthase (NOS), COX, and/or cP450.
We concluded that in response to bradykinin, the glo-
merulus releases both vasodilator and vasoconstrictor
eicosanoids that act in a paracrine manner to help control
downstream efferent arteriole resistance.
METHODS
We used methods similar to those described previously
to isolate the efferent arteriole with glomerulus and af- Fig. 1. Schematic illustration of orthograde (top) and retrograde perfu-
sion (bottom) of the efferent arteriole (Ef-Art). During orthogradeferent arteriole intact [2, 10]. Kidneys of young male
perfusion, the perfusate passes through the glomerulus, and vasoactiveNew Zealand white rabbits (1.5 to 2.0 kg) were removed autacoids released by the glomerulus will affect the downstream efferent
and sliced longitudinally along the corticomedullary axis. arteriole. During retrograde perfusion, autacoids released by the glo-
merulus will not affect the upstream efferent arteriole. AbbreviationsThe slices were placed in ice-cold minimum essential
are: Af-Art, afferent arteriole; Pre-pip, pressure pipette; Perf-pip, perfu-medium (MEM) (Gibco, Grand Island, NY) containing
sion pipette.
5% bovine serum albumin (BSA) (Intergen, Purchase,
NY), and a single superficial efferent arteriole with glo-
merulus and afferent arteriole intact was microdissected
under a stereomicroscope. Using a micropipette, the stricted with norepinephrine to approximately 40% of
preparation was transferred to a temperature-regulated the original diameter, after which bradykinin at 0.01 to
chamber mounted on the stage of an inverted microscope 10 nmol/L was added to the perfusate to generate a dose-
with Hoffmann modulation, and oxygenated MEM con- response curve. Luminal diameter was measured imme-
taining 5% BSA was perfused through the glomerulus diately before adding bradykinin and observed for at
from the end of the afferent arteriole. The perfusion least 10 minutes at each dose. After a 20-minute wash-
and pressure pipettes were advanced to the end of the out period, a second bradykinin dose-response curve was
afferent arteriole, and intraluminal pressure was main- generated.
tained at 50 mm Hg as measured by Landis’ technique. Effect of COX inhibition on bradykinin-induced dilata-
Thus, because the perfusate traveled through the glomer- tion. We examined whether vasodilator prostaglandins
ulus, hormonal factors released by the glomerulus would mediate bradykinin-induced dilatation. We first gener-
be able to reach the downstream efferent arteriole. The ated a control dose-response curve by adding bradykinin
bath, which was exchanged continuously, was similar to
to the efferent arteriole perfusate, then added 50 mol/Lthe perfusate, except that it contained 0.15% BSA. Fig-
indomethacin to both bath and lumen for 20 minutesure 1 represents a schematic illustration of the prepara-
and generated a second bradykinin dose-response curve.tion we used to perfuse the efferent arteriole either or-
Effect of 20-hydroxyeicosa-6(Z),15(Z)-dienoic acid (20-thograde (through the glomerulus) or retrograde.
HEDE), an inhibitor of [20-hydroxyeicosatetraenoic acidMicrodissection and cannulation were completed within
20-HETE)] and COX inhibition on bradykinin-induced90 minutes at 8C, after which the bath was gradually
dilatation. We tested whether a specific inhibitor of 20-warmed to 37C for the rest of the experiment. Once
HETE, 20-HEDE, reverses the effect of indomethacintemperature was stable, a 90-minute equilibration period
when perfused orthograde. The dose response to brady-was allowed before any measurements were taken. Im-
kinin was examined as in protocol 2, except that beforeages of the efferent arteriole were displayed at magnifi-
the second dose-response curve 20-HEDE (1 mol/L) wascations up to 1980 and recorded with a video system.
added to the lumen in the presence of indomethacin forThe diameter was measured with an image analysis system.
20 minutes and the effect of bradykinin was examined.
Experimental protocols Direct effect of 20-HETE on the efferent arteriole. To
test the direct action of 20-HETE, we perfused the effer-Response of the efferent arteriole to bradykinin. The
ent arteriole retrograde from its distal end to eliminatevasodilator action of bradykinin was examined in pre-
the influence of the glomerulus as described previouslyconstricted efferent arterioles, because the isolated effer-
[2]. After a 30-minute equilibration period, 20-HETE atent arteriole has little intrinsic tone. After a 30-minute
equilibration period, the efferent arteriole was precon- 0.001 to 1 mol/L was added to the perfusate. Luminal
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diameter was measured immediately before adding 20-
HETE and observed for at least 10 minutes at each dose.
Effect of a selective epoxygenase inhibitor on bradyki-
nin-induced dilatation. We examined whether EETs me-
diate bradykinin-induced dilatation, using the selective
epoxygenase inhibitor N-methylsulphonyl-6-(2-propar-
glyloxyphenyl)hexanamide (MS-PPOH). First, we gen-
erated a control dose-response curve by adding bradykinin
to the preconstricted efferent arteriole in the presence
of indomethacin and 20-HEDE, then added 1 mol/L
MS-PPOH to the lumen for 20 minutes in the presence
of indomethacin and 20-HEDE and generated a second
bradykinin dose-response curve.
Effect of NO synthesis inhibition on bradykinin-induced
dilatation. We examined whether NO mediates brady-
kinin-induced dilatation. An inhibitor of NO synthesis,
N-nitro-l-arginine (L-NAME), was added to the perfu-
sate at a dose of 0.1 mol/L and the effect of bradykinin
examined as in protocol 2. We have previously reported
Fig. 2. Effect of cyclooxygenase inhibition on bradykinin-induced va-that this concentration of L-NAME abolishes acetylcho-
sodilatation when the preconstricted efferent arteriole (Ef-Art) wasline-induced dilatation in rabbit efferent arterioles [10].
perfused orthograde. Pretreatment with 50 mol/L indomethacin mark-
edly attenuated bradykinin-induced dilatation (N  7). *P  0.05,Statistics untreated () vs. indomethacin () .
Values are expressed as mean  SE. Analysis of vari-
ance (ANOVA) was used to analyze overall change,
using dose as the repeated measure. Each dose was com-
fused orthograde to see whether the glomerulus releasespared to baseline or norepinephrine preconstriction us-
vasoactive prostanoids that regulate efferent arterioleing a paired t test. ANOVA and Dunnett’s method were
tone. Although indomethacin did not alter basal diame-used to adjust for multiple comparisons to baseline.
ter, it almost completely blocked bradykinin-induced di-When significant interactions were found between dose
latation of efferent arterioles. Bradykinin at 0.1, 1, andand treatment group, paired t tests were run at each dose
10 nmol/L increased diameter from 8.0 0.5 m to 8.4to determine at which dose(s) luminal diameter after
0.5 m, 9.1  0.6 m, and 9.3  0.6 m, respectively,treatment was different from luminal diameter before
treatment. Hochberg’s method was used to adjust the significantly less than control (N  7; P  0.0001 vs.
alpha level of significance for multiple comparisons. P without indomethacin) (Fig. 2). These data suggest that
0.05 was considered significant. when the glomerulus is stimulated with bradykinin, it
releases vasodilator prostanoids that dilate the efferent
arteriole.RESULTS
Response of the efferent arteriole to bradykinin Effect of 20-HEDE (a specific inhibitor of 20-HETE)
When the efferent arteriole was constricted with nor- and COX inhibition on bradykinin-induced dilatation
epinephrine, it was dilated by bradykinin in a dose-depen- We tested whether a specific inhibitor of 20-HETE
dent manner. Bradykinin dilated the efferent arteriole would reverse indomethacin blockade of bradykinin-
from 8.0  0.5 m to 10.0  0.5 m, 11.5  0.6 m,
induced dilatation. Pretreatment with indomethacin andand 12.6  0.4 m (N  6) at 0.1, 1, and 10 nmol/L,
20-HEDE (1 mol/L) did not affect basal diameter ofrespectively. When the dose-response curve was re-
the efferent arteriole. In the presence of indomethacinpeated, the efferent arteriole was dilated from 8.8  0.6
and 20-HEDE, bradykinin caused the same vasodilata-m to 10.3  0.3 m, 11.7  0.4 m, and 13.0  0.3 m
tion as when both agents were absent. At 0.1, 1, and 10at 0.1, 1 and 10 nmol/L, respectively. The first and second
nmol/L, diameter increased from 6.6 0.7 m to 11.4 dose-response curves were similar, and no tachyphylaxis
0.6 m, 12.6  0.5 m, and 13.2  0.5 m, respectivelywas observed.
(N  6) (Fig. 3). Thus, pretreatment with 20-HEDE
Effect of COX inhibition on bradykinin- reversed the effect of indomethacin (Figs. 2 and 3), sug-
induced dilatation gesting that during inhibition of prostaglandin synthesis,
release of 20-HETE opposes the vasodilator effect ofWe tested the effect of indomethacin on bradykinin-
induced dilatation of the efferent arteriole when per- bradykinin.
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Fig. 3. Effect of a selective 20-hydroxyeicosatetraenoic acid (20-HETE)
Fig. 5. Effect of the selective epoxyeicosatrienoic acid (EET) inhibitorinhibitor, 20-hydroxyeicosa-6(Z),15(Z)-dienoic acid (20-HEDE), on
N-methylsulphonyl-6-(2-proparglyloxyphenyl)hexanamide (MS-PPOH)bradykinin-induced vasodilatation when the preconstricted efferent ar-
on bradykinin-induced dilatation of the preconstricted efferent arteri-teriole (Ef-Art) was perfused orthograde in the presence of indometha-
ole (Ef-Art) when it was perfused orthograde in the presence of indo-cin. Adding 1 mol/L 20-HEDE to the lumen reversed the effect of 50
methacin and 20-hydroxyeicosa-6(Z),15(Z)-dienoic acid (20-HEDE).mol/L indomethacin (N  6). *P  0.05, untreated () vs. 20-HEDE
Adding 1 mol/L MS-PPOH to the Ef-Art lumen completely abolishedand indomethacin ().
bradykinin-induced dilatation (N  6). *P  0.05, with () vs. without
MS-PPOH ().
Effect of a selective epoxygenase inhibitor on
bradykinin-induced dilatation
To confirm that EETs mediate bradykinin-induced di-
latation, we examined the effect of blocking EETs, using
the specific EET synthesis inhibitor MS-PPOH at 1mol/L
in the presence of indomethacin and 20-HEDE. During
pretreatment with indomethacin and 20-HEDE, brady-
kinin dilated the efferent arteriole from 7.5  0.4 m to
9.8  0.7 m, 11.8  0.4 m, and 12.7  0.6 m at 0.1,
1, and 10 nmol/L, respectively. MS-PPOH pretreatment
completely abolished bradykinin-induced dilatation; di-
ameter remained unchanged, going from 7.6  0.6 m to
7.4  0.6 m, 7.1  0.7 m, and 7.3  0.5 m at 0.1, 1,
and 10 nmol/L, respectively (N 6; P 0.001 vs. without
MS-PPOH) (Fig. 5).
Effect of NO synthesis inhibition onFig. 4. Direct effect of 20-hydroxyeicosatetraenoic acid (20-HETE) on
the diameter of the efferent arteriole (Ef-Art) when it was perfused bradykinin-induced dilatation
retrograde. When 1 nmol/L to 1 mol/L 20-HETE was added to the
To investigate whether NO is released in response toEf-Art lumen, it caused dose-dependent vasoconstriction (N  6) *P
0.05 vs. basal diameter. bradykinin and reaches the efferent arteriole in sufficient
quantities to induce dilatation, we examined the effect of
the nonselective NO synthase (NOS) inhibitor L-NAME.
Direct effect of 20-HETE on the efferent arteriole After L-NAME pretreatment, basal diameter was 10.8
0.3 m (N  6). When efferent arterioles were precon-When we perfused efferent arterioles retrograde, 20-
stricted to 6.0 0.5 m with norepinephrine, bradykininHETE caused dose-dependent vasoconstriction at 0.1
dilated L-NAME–treated arterioles the same as thoseand 1 mol/L. Diameter decreased to 78% and 59% of
baseline, respectively (N  6; P  0.05) (Fig. 4). not treated with L-NAME. Thus, in response to bradyki-
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There is evidence that the glomerulus may control its
own capillary pressure by releasing vasoactive substances
that, in turn, regulate the resistance of the downstream
efferent arteriole [2, 10]. COX is present in the glomeru-
lus [11] and renal vessels [25] and is capable of synthesiz-
ing prostaglandins. We have shown that downstream
efferent arteriole resistance may be regulated by prosta-
glandins released by the upstream glomerulus [2]. Changes
in kinin generation reportedly have profound effects on
prostaglandin levels within the kidney [5], and prosta-
glandins may contribute to the effects of kinins on salt
and water excretion [14]. It is possible that bradykinin
controls resistance of the downstream efferent arteriole
either directly or indirectly by releasing vasoactive sub-
stances from the glomerulus. In our previous studies
examining the direct action of bradykinin on rabbit effer-
ent arterioles perfused retrograde, we found that its vaso-
dilator effect was not blocked by indomethacin, sug-
gesting that unlike the glomeruli, the efferent arteriole
Fig. 6. Effect of nitric oxide (NO) synthesis inhibition on bradykinin- did not release the vasoconstrictor 20-HETE. However,
induced dilatation of the preconstricted efferent arteriole (Ef-Art) when
in the present study, we perfused the efferent arterioleit was perfused orthograde. N-nitro-l-arginine (L-NAME) pretreat-
ment did not block bradykinin-induced dilatation (N  6). Symbols orthograde (through the glomerulus) and found that bra-
are: (), untreated; (), 100 mol/L L-NAME. dykinin-induced dilatation could be markedly attenuated
by the COX inhibitor indomethacin. Our data indicate
that when the glomerulus is stimulated by bradykinin
it releases cyclooxygenase metabolites (prostaglandins),nin, the glomeruli do not release enough NO to alter
which, in turn, control efferent arteriole resistance.efferent arteriole tone (Fig. 6).
Recently, a number of studies have focused attention
on a possible physiologic role of cP450 metabolites of
DISCUSSION arachidonic acid in regulating vascular tone. In the kid-
ney, cP450 enzymes metabolize arachidonic acid to aIn the present study, we examined whether bradykinin
stimulates the release of vasoactive autacoids from the series of EETs and 20-HETEs [13]. The physiologic im-
portance of 20-HETE in the control of renal hemo-glomerulus that regulate efferent arteriole tone. We
found that bradykinin-induced vasodilatation can be dynamics has been studied extensively. Those studies
suggested that 20-HETE may participate in tubuloglo-blocked by indomethacin. This is in contrast to our previ-
ous finding that when efferent arterioles were perfused merular feedback [28], as well as in the myogenic response
of the afferent arteriole [8], and is therefore importantretrograde to avoid the influence of the glomerulus, bra-
dykinin-induced dilatation was not blocked by indo- for renal blood flow autoregulation [29]. On the other
hand, several recent studies suggest that EET is the endo-methacin [20]. The expected direct vasodilator effect of
bradykinin on the efferent arteriole was not observed in thelium-derived hyperpolarizing factor (EDHF) [4, 6],
which may be important in the control of glomerularthe presence of indomethacin, suggesting that the glo-
merulus releases not only vasodilator but also vasocon- hemodynamics. Imig et al [7] demonstrated that when
renal microvessels are stimulated by bradykinin, theystrictor autacoids. Indeed, we found that the 20-HETE
inhibitor, 20-HEDE, reversed the effect of indometha- produce EETs, which, in turn, dilate the afferent arteri-
ole. We have also shown that in efferent arterioles per-cin. Also, the selective EET inhibitor MS-PPOH com-
pletely abolished the vasodilator action of bradykinin in fused retrograde, bradykinin-induced dilatation is medi-
ated by cP450 metabolites, probably EETs [20]. In thethe presence of indomethacin and 20-HEDE. We con-
cluded that in response to bradykinin, the glomerulus present study, with the efferent arteriole perfused ortho-
grade, we found that the dilatation produced by bradyki-releases COX metabolites (probably prostaglandins) that
have a vasodilator effect. When COXs are inhibited, the nin was blocked by indomethacin, but when the efferent
arteriole was perfused retrograde the dilatation pro-vasoconstrictor 20-HETE released by the glomerulus is
able to oppose the vasodilator effect of bradykinin. This duced by bradykinin occurred via cP450 metabolites
(EETs) but not prostaglandins [20], raising the possibilityvasodilator effect is mediated by EETs released by the
glomerulus and/or the efferent arteriole and does not that the glomerulus releases not only vasodilators (pros-
taglandins) but also a vasoconstrictor (probably 20-HETE).involve NO.
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To confirm this, we pretreated the efferent arteriole with NO. Our previous study showed that pretreating afferent
a specific inhibitor of 20-HETE (20-HEDE) and indo- arterioles with L-NAME failed to affect their response
methacin. We found that 20-HEDE reversed the effect to bradykinin [27]. Thus, although in many arteries the
of indomethacin, suggesting that bradykinin stimulates vasodilator effect of bradykinin is partly dependent on
the glomerulus to release 20-HETE. NO, this does not appear to be the case in the efferent
To see whether the dilatation produced by bradykinin arteriole.
in the presence of indomethacin and 20-HEDE involves
EETs, we used a selective EET inhibitor, MS-PPOH.
CONCLUSIONDuring pretreatment with indomethacin and 20-HEDE,
In conclusion, we examined the role of paracrine fac-MS-PPOH completely blocked the vasodilator action
tors released by the glomerulus in response to bradykininof bradykinin. Taken together, our results suggest that
in the efferent arteriole. Our results suggest that whenbradykinin stimulates the glomerulus to release not only
the glomerulus is stimulated with bradykinin, it regulatesvasodilator prostaglandins but also probably the cP450
efferent arteriole tone by releasing a vasodilator and/ormetabolite 20-HETE, which counteracts the vasodilator
a vasoconstrictor, which are COX and cP450 metaboliteseffect of EETs in the downstream efferent arteriole. In
of arachidonic acid. The glomeruli do not release enoughprevious studies, we have shown that when the efferent
NO in response to bradykinin to alter efferent arteriolearteriole is perfused retrograde the vasodilator effect
tone. In addition, this study also suggests that the glomer-of bradykinin is mediated by EETs released from the
ulus may play an important role in regulation of theefferent arteriole. Under our present experimental con-
downstream circulation.ditions it was not possible to determine whether the
EETs are produced only by the efferent arteriole or by
the glomerulus. However, it is possible that the glomeru- ACKNOWLEDGMENT
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